SARS-CoV-2 Pneumonia Has Low Prevalence of Bacterial Identification
The prevalence of early bacterial identification is up to 3-fold lower in intubated patients with SARS-CoV-2 pneumonia compared with patients with influenza pneumonia.
Pneumonia
FDA Approves 20-Valent Pneumococcal Conjugate Vaccine Prevnar 20
The vaccine contains capsular polysaccharide conjugates for 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F and 33F) that cause invasive pneumococcal disease.
Suvratoxumab Not Effective for Staphylococcus aureus Pneumonia in the ICU
Researchers report findings from SAATELLITE, a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial that assessed the safety and efficacy of suvratoxumab for Staphylococcus aureus pneumonia.
Oral-Only Dosing Regimen of Omadacycline Approved for CABP
Previously, the initial loading dose of Nuzyra for CABP was administered only by IV infusion.
ATS Guideline Addresses Testing for Viral Pathogens in Community-Acquired Pneumonia
Nucleic acid-based viral diagnostics are suggested for hospitalized patients with suspected community-acquired pneumonia.
Elevated Albuminuria May Be Linked to Chronic Lower Respiratory Disease Mortality
Elevated albuminuria may be associated with subsequent mortality from chronic lower respiratory disease and from influenza and pneumonia.
Novel Pneumococcal Conjugate Vaccine Immunogenic, Safe in Pediatric Trials
Positive topline results were announced from two phase 3 studies evaluating V114, an investigational 15-valent pneumococcal conjugate vaccine, in pediatric patients for the prevention of invasive pneumococcal disease.
Lefamulin May Offer Alternative in Community-Acquired Bacterial Pneumonia
In patients with community-acquired bacterial pneumonia, lefamulin may offer a much-needed IV/oral empiric monotherapy alternative to other antibiotic classes.
Definitive and Indeterminate Pseudomonas aeruginosa Pneumonia Among Patients With CAP
A team of investigators sought to determine the prevalence of definitive and
indeterminate Pseudomonas aeruginosa pneumonia among patients with CAP.
No Significant Differences With Mavrilimumab vs Placebo in Severe COVID-19
Researchers evaluated the effect of mavrilimumab on the outcomes of patients with COVID-19 pneumonia and systemic hyperinflammation.
- Loading...
Loading...
Next post in Lung Infection
Loading... 
Loading...